Abstract

BackgroundThe economic burden of ulcerative colitis (UC), specifically related to indirect costs, is not extensively documented. Understanding and quantifying it is required by health care decision makers.AimTo assess the impact of indirect costs of UC in observation studies.MethodA systematic literature search was conducted in MEDLINE®, Embase® and Cochrane Library to capture all relevant publications reporting outcomes on absenteeism, presenteeism and productivity losses in moderate to severe UC. Eligibility criteria for inclusion into the review were established using a predefined PICOS scheme. All costs were adjusted to 2017 currency values (USD dollars, $).ResultsIn total, 18 studies reporting data on indirect costs were included in the analysis. Absenteeism costs were classified into three categories: sick leave, short-term and long-term disability. Most of the studies captured absenteeism costs related specifically to sick leave, which was experienced on average by 10 to 24% patients with UC. Only three studies captured presenteeism costs, as these are difficult to measure, however costs ranged from 1602 $ to 2947 $ per patient year. The proportion of indirect costs accounted for 35% of total UC costs (Total UC costs were defined as the sum of healthcare costs, productivity costs and out-of-pocket costs).DiscussionA limited number of studies were identified describing the indirect costs in patients with moderate to severe UC. Insufficient data on different components of costs allowed a limited analysis on the impact of indirect costs in patients with UC. Further studies are needed to gain an understanding of the influence of UC on patients’ functional abilities.

Highlights

  • The economic burden of ulcerative colitis (UC), related to indirect costs, is not extensively documented

  • The proportion of indirect costs accounted for 35% of total UC costs (Total UC costs were defined as the sum of healthcare costs, productivity costs and out-of-pocket costs)

  • The management of UC has changed with the approval of new biological therapies such as infliximab, which was approved by the Food and Drug Administration (FDA) (2005) and by the European Medicines Agency (EMA) (2006) for the treatment of moderate to severe UC [5, 6]

Read more

Summary

Introduction

The economic burden of ulcerative colitis (UC), related to indirect costs, is not extensively documented. Understanding and quantifying it is required by health care decision makers. Apart from the clinical repercussions associated with this disease, UC has a societal burden on patients and their caregivers. The economic burden of UC, Constantin et al BMC Gastroenterology (2019) 19:179 related to indirect costs, has not been extensively documented. As indirect costs account for a significant percentage of total UC costs, understanding and quantifying the economic burden of UC is required by health care systems to control and avoid costs associated to productivity losses in a societal perspective [7, 8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.